Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by progressive loss of motor neurons, gliosis, neuroinflammation and oxidative stress. The aim of this study was to evaluate the involvement of NADPH oxidases (NOX) in the oxidative damage and progression of ALS neuropathology. We examined the pattern of NOX expression in spinal cords of patients and mouse models of ALS and analyzed the impact of genetic deletion of the NOX1 and 2 isoforms as well as pharmacological NOX inhibition in the SOD1 G93A ALS mouse model.
a b s t r a c t
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by progressive loss of motor neurons, gliosis, neuroinflammation and oxidative stress. The aim of this study was to evaluate the involvement of NADPH oxidases (NOX) in the oxidative damage and progression of ALS neuropathology. We examined the pattern of NOX expression in spinal cords of patients and mouse models of ALS and analyzed the impact of genetic deletion of the NOX1 and 2 isoforms as well as pharmacological NOX inhibition in the SOD1 G93A ALS mouse model.
A substantial (10-60 times) increase of NOX2 expression was detected in three etiologically different ALS mouse models while up-regulation of some other NOX isoforms was model-specific. In human spinal cord samples, high NOX2 expression was detected in microglia. In contrast to previous publications, survival of SOD1 G93A mice was not modified upon breeding with constitutive NOX1 and NOX2 deficient mice. As genetic deficiency of a single NOX isoform is not necessarily predictive of a pharmacological intervention, we treated SOD1 G93A mice with broad-spectrum NOX inhibitors perphenazine and thioridazine. Both compounds reached in vivo CNS concentrations compatible with NOX inhibition and thioridazine significantly decreased superoxide levels in the spinal cord of SOD1 G93A mice in vivo. Yet, neither perphenazine nor thioridazine prolonged survival. Thioridazine, but not perphenazine, dampened the increase of microglia markers in SOD1 G93A mice. Thioridazine induced an immediate and temporary enhancement of motor performance (rotarod) but its precise mode of action needs further investigation. Additional studies using specific NOX inhibitors will provide further evidence on the relevance of NOX as drug targets for ALS and other neurodegenerative disorders. Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/freeradbiomed
Introduction
Amyotrophic lateral sclerosis (ALS) is a disease leading to motor neuron degeneration, paralysis and death usually within five years following diagnosis. Currently there is no cure for ALS. New therapies and identification of novel pharmacological targets are urgently needed. The etiology of the disease appears multiple, but remains unclear for most cases. A strong neuroinflammation in the brain stem and spinal cord parenchyma is believed to contribute to ALS progression. At the pathological level, neuroinflammation is characterized by the proliferation and activation of microglia and astrocytes, accompanied by the invasion of the central nervous system (CNS) parenchyma by inflammatory cells. Although neuroinflammation may be neuroprotective in some instances, excessive production of pro-inflammatory cytokines and reactive oxygen species (ROS) is believed to contribute to disease progression [1] .
ROS are important signaling molecules necessary for a range of physiological processes. However, excessive production of ROS causes damage of biomolecules interfering with their normal functions and leading ultimately to cellular dysfunction or even death. A major source of ROS in the CNS is the family of NADPH oxidases (NOX) [2] . NOX are transmembrane proteins comprising 7 members (NOX1-NOX5, DUOX1 and DUOX2), each with a specific tissue distribution and activation mechanism [3] . NOX catalyze the reduction of molecular oxygen to superoxide radical anion (O 2 • À ), which in turn can give rise to other ROS, such as hydrogen peroxide (H 2 O 2 ) and hypochlorous acid (HOCl) [4] . Recent studies have shown that genetic deletion of NOX isoforms is neuroprotective in mouse models of Parkinson's disease [5] , stroke [6] , and prion disease [7] . Previous studies have proposed NOX1 and NOX2 as potential drug targets since they contribute to disease progression in a mouse model of ALS [8, 9] . Moreover, it was recently shown that NOX2 activity in peripheral neutrophils of ALS patients has a prognosis value for disease outcome as lower NOX2 activity correlated with increased survival [9] . However, the therapeutic relevance of NOX inhibition remains unclear as validated specific small molecule NOX inhibitors are only emerging [10, 11] . We have recently found that some N-substituted members of the phenothiazine family inhibit NOX isoforms 1-5 [12] . Phenothiazines have numerous pharmacological properties [13] , and are used in humans as antipsychotics and antiemetics. Since they cross the blood-brain barrier (BBB), we hypothesized that they may inhibit NOX activity in ALS spinal cord, curb neuroinflammation and slow down the progression of the disease. To test this hypothesis, we administered perphenazine or thioridazine to SOD1
G93A mice, a model of familial ALS, and evaluated the effect on clinical symptoms and molecular markers of the disease.
Methods

Chemicals and reagents
Hank's buffered salt solution (HBSS), fetal bovine serum (FBS) and Amplex Red were purchased from Invitrogen. Thioridazine hydrochloride, perphenazine, penicillin, streptomycin, phorbol myristate acetate (PMA), diphenylene iodonium chloride (DPI), dimethyl sulfoxide, superoxide dismutase 1 bovine (Cu/Zn SOD1), catalase and Tween-20 were purchased from Sigma Aldrich. 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-1) was acquired from Dojindo Molecular Technologies.
RA2 Cells
The granulocyte macrophage colony-stimulating factor (GM-CSF)-dependent Ra2 microglia cell line generated by spontaneous immortalization of primary mouse microglia [14] was cultured in minimal essential medium with 10% fetal calf serum, 8 ng/ml GM-CSF, penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37°C and 5% CO 2 . RA2 cells were plated in 96 well plates at a density of 10000 cells/well and treated with 5 mg/ml LPS (ALX-581-007-L002, Enzo Life Sciences) 24 h after plating for additional 24 h.
ROS measurements in intact cells
Levels of H 2 O 2 produced by intact cells were measured using Amplex Red fluorescence as described [15] . The concentration of O 2
• À was measured as absorbance change of 1 mM WST-1 at 440 nm [16] . Fluorescence and absorbance were measured in a FluoSTAR OPTIMA, BMG labtech instrument at 37°C. Under the conditions of pre-treatment with LPS and stimulation with PMA, macrophages produce peroxynitrite [17] , which can generate fluorescence in the HRP/Amplex red system [18] . The signal measured in microglial RA2 cells upon PMA stimulation is specific for H 2 O 2 and O 2 • À as it is inhibited in a concentration-dependent manner by catalase in Amplex assay and by SOD in WST1 assay ( Supplementary Fig 1) .
Real-time quantitative polymerase chain reaction
RNA was extracted from mouse spinal cords (SOD1 G93A mice), total brain (TDP43 and FUS mice) or from RA2 cells using the Qiagen RNeasy mini kit following the manufacturer's instructions. RNA concentration was determined using Nanodrop. 500 ng was used for cDNA synthesis using Takara PrimeScript RT reagent Kit following manufacturer's instruction. Real-time PCR was performed using SYBR green assay on a 7900HT SDS systems from ABI at the Genomics Platform, National Center of Competence in Research Frontiers in Genetics, Geneva. The efficiency of each primer was verified with serial dilutions of cDNA. Relative expression levels were calculated by normalization to geometric mean of the two house-keeping genes HPRT and GAPDH, as described previously [19] . The highest normalized relative quantity was arbitrarily designated as a value of 1.0. Fold changes were calculated from the quotient of means of these normalized quantities and reported as 7 SEM. Sequences of all primers used in this study are provided in Supplementary Table 1 . Threshold cycle (Ct) values for NOX subunits corresponding to the intersection between an amplification curve and a threshold line set at 0.20 by the software are provided in Supplementary Table 2.
Thioridazine and perphenazine determination in brain
Perphenazine (3 mg/kg) or thioridazine (10 mg/kg) were administered i.p. After a desired time period (30 min -8 h) mice were sacrificed by lethal injection of Nembutal and perfused with 0.9% saline solution intracardially for 5 min. Brains were dissected, snap frozen in liquid nitrogen, and stored at À 80°C. Brains were weighted and homogenized in 2 ml of deionized water. The final volume was adjusted to 5 mL with water. To 500 mL of homogenate, 100 mL of desmethylclobazam-d5 (internal standard) at 10 ng/mL and 3 mL of hexane/ethyl acetate (50/50 mixture) were added. Liquid-liquid extraction was performed by shaking samples for 30 min. After centrifugation at 1000 g for 10 min, the supernatant was removed, evaporated and the residue reconstituted in 200 mL of MeOH/water (1:1, v/v). Finally, 20 mL were injected onto the HPLC system. Along with the unknown samples, QC and standards samples, prepared using blank brain spiked with thioridazine and perphenazine, covering the expected concentration range were processed. All experiments were performed using an API 4000 triple quadrupole mass spectrometer (AB Sciex, Concord, ON, Canada) controlled by Analyst 1.5.1 software. The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode with positive electrospray ionization. The MRM transitions were 371.1-126.1, 404.1-171.1 and 292.1-249.8 with a dwell time of 50 ms for thioridazine, perphenazine and IS (desmethylclobazam-d5), respectively. The instrument was directly coupled to an Agilent series 1100 (Waldbronn, Germany) LC system. Chromatography was performed on a Phenomenex Kinetex C18 analytical column (50 mm Â 2.1 mm, 2.6 μm; Torrance, CA, USA) preceded by a pre-column with the same phase. Flow rate was 0.5 mL/min using gradient elution conditions. The method was fully validated before application to this study. The concentration of drugs was normalized to brain tissue weight and expressed in mg/ml brain tissue assuming a brain density of 1.04 g/mL [20] . The normalization to volume was needed for the presentation of the IC50 values for phenothiaizine compounds (mg/ ml) on the same graph.
2.6. In vivo labelling with dihydroethidium (HE) and detection of reactive species by LC/MS/MS HE stock solution (25 mg/ml) was prepared on the day of the experiment in argon-purged DMSO under an argon-enriched atmosphere and with protection from light. 7.5 ml of this solution was mixed with 7.5 ml 0.9% NaCl and injected intraspinally into SOD1 G93A mice (110 days). After 30 min mice were anesthetized with Nembutal and perfused intracardially for 5 min with 0.9% saline. Spinal cord was dissected, snap frozen and stored at À80°C. Products of HE oxidation were quantified using LC/MS/MS analysis as described previously [21] .
Western blotting
Protein extracts were prepared by lysing the spinal cord tissue in the buffer containing: 50 mM Tris-HCl pH 7.4; 50 mM NaCl; 10 mM MgCl2; 1 mM EGTA; 1% Triton-X100; Protease inhibitors (Roche). BioRad assay was used for protein quantification. Equal amount (30 mg) of protein was loaded for analysis. After transfer, the membrane was blocked for 1 h at room temperature in PBS/ 0.5% Tween-20 buffer containing 5% fat-free milk (blocking buffer). The membrane was incubated at 4°C overnight with gp91 phox antibody (BD Transduction Laboratories, BD611415; 1/500 diluted in blocking buffer). After washing, the membrane was incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (1/10,000 in blocking buffer). Unbound secondary antibody was washed off. ECL kit (GE Healthcare) was used to detect the signal.
Immunohistochemistry
Mice were anesthetized with Nembutal (i.p) and perfused intracardially with cold PBS followed by cold 4% paraformaldehyde (Sigma Aldrich, Saint Louis, USA). Spinal cords were removed and stored for 24 h in 4% paraformaldehyde. Lumbar sections were embedded in paraffin, cut in 10-mm-thick sections, and mounted on glass slides. Deparaffinization was performed by a gradient of alcohols. In order to expose the epitopes, tissues were boiled in citrate buffer (0.01 mol/L, pH ¼6) for 15 min. Prior to addition of antibodies, unspecific binding was prevented by incubation of tissues in blocking solution (0.2% Triton-X, 10% fetal calf serum, PBS) for 30 min. Incubation overnight was performed at 4°C with either rabbit polyclonal Iba1 (Wako, 1:500) or mouse monoclonal glial fibrillary acidic protein (GFAP; MAB360, Chemicon, 1:1000) diluted in buffer (0.2% Triton-X100, PBS). Tissues were incubated with secondary antibodies Alexa Fluor (A21424 and A11034, Invitrogen, 1:1000) for 30 min, DAPI for 10 min and mounted with FluorSave (Calbiochem, San Diego). For visualization of neurons, tissues were deparaffinized, stained with 0.1% cresyl violet for 5 min, and then dehydrated by a gradient of alcohols. Technical controls were performed for each experiment by omitting the first antibody and performing the other steps of the procedure (data not shown). Motor neurons were counted manually in the anterior horn of mouse spinal cord slices. The intensity of Iba1 and GFAP staining was analyzed using ImageJ software.
Immunostaining in human tissues
Patients
Human tissue samples used in this study (Table 1) 
Immunohistochemistry
NOX2 staining was performed as described in [7] . Briefly, antihuman NOX2 (1:250, Clone 48, Sanquin) antibody was applied to sections after deparaffinization and antigen retrieval. Staining was visualized using DAB (Sigma-Aldrich) and H 2 O 2 (Sigma-Aldrich), after incubation with a biotinylated secondary antibody (Vector Laboratories) and the ABC complex solution (Vector laboratories). Hematoxylin counterstain was subsequently performed. Quantification of NOX2 expression in spinal cord sections was performed as described before [7] on regions of interest drawn on different areas of spinal cord sections.
Animals used in the study
B6SJL-Tg(SOD1
G93A
)1Gur/J (Stock Number: 002726) [22] mice were purchased from Jackson laboratory and kept in standard conditions in the conventional animal facility of Centre Médical Universitaire of the University of Geneva with free access to food and water. All experiments were approved by the local veterinary office and the Commission for Animal Experimentation of the Canton of Geneva, Switzerland, authorization number 1005/3445/2-R.
To generate ALS mice deficient for NOX2, B6SJL-Tg (SOD1 G93A )1Gur/J males were crossed with homozygous NOX2KO 
SOD1 G93A mice treatment
Litters were split to enable even distribution of parentage between the two comparison groups, and the groups were randomly assigned to treatment or control. Thioridazine solution was prepared in NaCl 0.9%. Perphenazine was solubilized in acidified 0.9% saline solution containing 0.005% acetic acid. Drugs and corresponding vehicles were administered in 250 mL intraperitoneally (i.p.). Injections were started when mice reached 70 days of age, before the obvious appearance of clinical symptoms. Animals were observed daily, weighed twice weekly and their motor function was assessed using a grid test and rotarod. Rotarod training was performed over three days with one 5 min trial per day. The rotarod (Ugo Basile 7650) was set to accelerate from 4 to 40 rpm over 300 s. Latency to fall was recorded in seconds (s) for each mouse. Motor tests were performed once a week in the afternoon. The survival endpoint was the loss of the righting reflex, i.e., the inability of the animals to right themselves within 30 s after being laid on each side. Animals were euthanized with terminal anesthesia by Nembutal injection followed by intracardiac PBS perfusion prior to the collection of samples for protein and RNA extraction. For immunohistochemistry, paraformaldehyde (4% in PBS) was perfused prior to collection of samples.
Statistical analysis
Data were analysed using Graph-Pad Prism software 6.03. Student's t-test was used for cell culture experiments; non-parametric Mann-Whitney test was used for the experiments performed on animal samples; a one-way ANOVA for repeated measures with Bonferroni's Multiple Comparison Test post-hoc analysis was used for behaviour experiments; log-rank (Mantel-Cox) Test was used for lifespan comparison of treated versus vehicle SOD1 G93A mice.
Results
NOX2 and its subunits are strongly up-regulated in ALS spinal cord in mice and humans
The expression levels of all six mouse NOX isoforms and their subunits were measured by qPCR using RNA isolated from the spinal cord of wild-type (120 days) and SOD1 G93A mice at early (90 days) and terminal stage of disease (120 days) (Fig. 1A) (Fig. 1A) . Consistent with mRNA expression data, NOX2 protein was strongly increased in spinal cord of SOD1 G93A mice (120 days) (Fig. 1B) . NOX mRNA expression was also measured in the spinal cord of two additional mouse models expressing ALS-causing genes, TDP-43 [23] and FUS/TLS [24] (Fig. 1C, D (Fig. 2) . A trend towards increased levels of NOX2 in different regions of the spinal cord was observed in the patients as compared to non ALS controls.
Genetic deletion of NOX1 and 2 isoforms does not affect survival of SOD1 G93A mice
To assess the impact of NOX1 and NOX2 on the progression of neurodegeneration in ALS, we bred NOX1 and NOX2-deficient mice (normal life span) with SOD1 G93A mice and evaluated their survival. No significant change in survival was observed in neither mice deficient in NOX1 (Suppl. Fig. 2 ) nor NOX2 (Fig. 3A, B) for both genders when compared to wild-type ALS littermates. Interestingly, we observed that the B6 background increased survival of the SOD1 G93A male mice as previously shown by others [25, 26] .
Thus, the comparison between matched littermates is necessary to evaluate the effects of NOX deletion. NOX2 deficiency did not have an impact on the expression of neuronal (neurofilament light polypeptide, NEFL), microglial (Iba1, CD68) and astroglial markers (GFAP) neither in males nor in females (Fig. 3C) . No obvious differences in morphology of activated microglia were detected in NOX2 deficient ALS mice (Suppl. Fig. 3 ). Constitutive genetic ablation has limitations for validating the relevance of NOX targeting in ALS as i) NOX activity may be involved in neuronal development [2] and adaptive mechanisms might develop to compensate NOX-dependent signaling; ii) presence of NOX may be protective at early stages of ALS [27] , iii) other NOX isoforms (e.g. NOX3, NOX4) might be involved in disease progression. Therefore, we also tested a pharmacological approach in order to inhibit all NOX, starting the treatment at early stage of disease (day 70).
N-substituted phenothiazine compounds inhibit NOX-derived ROS generation by microglial cells
The two N-substituted phenothiazine compounds, perphenazine and thioridazine (Fig. 4A) , were chosen based on previous pharmacological characterization [12] for evaluation in an in vitro model of microglia activation. Pretreatment of cultured mouse microglial cells RA2 with 5 mg/mL LPS from Escherichia coli (Serotype R515 (Re)) lead to activated microglial morphology and increased expression of NOX2 (Fig. 4B) that was accompanied by an increase in PMA-induced production of ROS (Fig. 4C-D, dark grey  versus light grey bars) . To evaluate the effect of the two G93A mice at different stages of disease (90 and 120 days, n ¼4 males) and for non-carrier littermates (120 days, n ¼ 4, males) for all NOX isoforms. NOX2 and NOX3 levels were strikingly increased and no change was observed for NOX1 and NOX4 levels while DUOX1 and DUOX2 levels were below detection level (data not shown). Consistent with NOX2 increase, the expression of subunits p22phox, p40phox, p47phox, p67phox and rac1 was increased already at early stage of disease, however the NOX1 and NOX3 subunits Noxo1 and Noxa1 were unchanged. DUOXA1 levels were increased with the progression of the disease. (Fig. 4C, D) . This indicated that the tested phenothiazines are able to diminish NOX2-derived ROS production by activated microglial cells, and they were further tested in vivo.
Pharmacokinetics of perphenazine and thioridazine in vivo
N-substituted phenothiazines are used in the clinic for CNS applications for over 50 years and their bioavailability in brain is well documented [28, 29] . To ensure that concentrations of drug sufficient for NOX inhibition are obtained in the CNS, we administered perphenazine (3 mg/kg) or thioridazine (10 mg/kg) i.p. to wild type mice and measured the brain content of each drug after 0.5, 1, 2, 4 and 8 h. The brain concentration of perphenazine (Fig. 5A) and thioridazine (Fig. 5B ) reached maximal level 2-4 h post injection, and these concentrations were above the respective IC 50 values for NOX2 inhibition (3.9 70.7 mM for perphenazine and 2.2 70.2 mM for thioridazine in cellular assays [12] ) at least for 8 h. The doses could not be increased to avoid the undesired sedative effect of these drugs.
Effect of thioridazine on spinal cord ROS generation in vivo
Increased expression of NOX2 leads to elevated oxidative modifications in ALS spinal cords [8] . Here, we assessed the specific reactive species generated in ALS spinal cords and NOX-inhibitory activity of thioridazine in vivo. For this, we used a LC/MS/ MS detection system to differentiate the products of HE oxidation in the spinal cord SOD1 G93A mice. In preliminary experiments we evaluated three different delivery routes for HE: i.p., i.v. and intraspinal injection. We noticed significant rapid oxidation of the probe in the plasma upon i.p. and i.v. injections (data not shown). In order to measure the specific oxidative activity occurring in the spinal cord parenchyma, we opted for direct intraspinal delivery of the probe for subsequent experiments. Thioridazine, 15 mg/kg, was administered to SOD1 G93A mice i.p. 2 h prior to HE injection.
The following HE oxidation products were detected and quantified in spinal cords: 2-hydroxyethidium (2-OH-E þ ), the specific product of the reaction of HE with O 2
and 2-chlorethidium (2-Cl-E þ ), a specific product formed from the reaction of HE with hypochlorous acid (HOCl) [21] . Consistent with an increase of oxidative stress in the ALS spinal cord, 2-OH-E þ ( Fig. 5C ) [30] and E þ dimer (Fig. 5E ), but not E þ (Fig. 5D ) were increased in spinal cords of SOD1 G93A mice during the clinical stage of the disease (110 days) as compared to NC littermates. We expressed these oxidation products relative to HE to account for possible differences in the concentration of the probe between animals. Indeed, standardization of results to HE improved the standard deviation. No difference in 2-chloroethidium (2-Cl-E þ ) (Fig. 5F ), an indicator of myeloperoxidase activity was observed in the spinal cord of SOD1 G93A mice. Mice treated with thioridazine had significantly lower levels of HE-normalized 2-OH-E þ , the specific product of O 2 • À -induced HE oxidation and the primary product formed by NOX2-than vehicle-treated controls. This indicated that thioridazine indeed decreased ROS generation in the spinal cord of SOD1 G93A mice, possibly through NOX2 inhibition (Fig. 5C ).
Effect of perphenazine and thioridazine on disease progression and survival of SOD1 G93A mice
To assess the efficacy of phenothiazine compounds in vivo in a mouse model of ALS perphenazine, thioridazine or their respective vehicles were administered i.p. daily to SOD1
G93A mice starting at 70 days of age until terminal stage. We started the treatment at early stage of disease in order to target the switch of microglial activation state from protective to inflammatory which coincides with increased expression of NOX2 [27] . A summary of the experimental details is shown in Table 2 . Survival of SOD1 G93A mice was evaluated following treatment with perphenazine (Fig. 6A) or thioridazine (Fig. 7A) . The average survival values are shown in Table 2 . None of the compounds significantly increased survival.
We assessed general progression of the disease by weight loss, motor performance (rotarod test), and muscle strength (time mice could stay upside down on a grid). Perphenazine treatment of SOD1 G93A mice resulted in significant improvement of body weight (Fig. 6B ), but only a non-significant trend was seen in the rotarod and grid tests (Fig. 6C, D) . Thioridazine treatment had no effect on weight loss of SOD1 G93A mice (Fig. 7B) . Motor function was enhanced in the rotarod test immediately after the start of treatment (Fig. 7C) ; however, the deterioration of rotarod performance was comparable in thioridazine and vehicle treated mice.
Muscle strength was not improved as shown by the grid test (Fig. 7D) .
Characterization of molecular markers
We further evaluated molecular changes in the spinal cord of SOD1 G93A mice by qPCR and immunohistochemistry. Pharmacological inhibition of NOX2 did not produce a neuroprotective effect as shown by levels of the neurofilament light polypeptide (NEFL) mRNA (Fig. 8A, B) and quantification of motor neurons (Fig. 8C) .
Perphenazine treatment resulted in a trend to an increased expression of mRNA for micro-and astroglial markers, with a statistically significant increase of CD68 expression. However this effect was not confirmed by evaluation of immunostaining for microglial marker Iba1. Surprisingly, perphenazine increased the expression of NOX2 mRNA in the spinal cord of treated mice. On the other hand, thioridazine significantly decreased the expression levels of microglial markers Iba1 and CD68; moreover, a similar trend was observed in immunostaining for Iba1 in lumbar spinal cords of SOD1 G93A mice. Also, we observed a trend towards a decrease in expression of the astrocyte marker GFAP both at mRNA and protein levels in these animals. Interestingly, none of the evaluated markers showed a difference in NOX2-deficient versus control ALS mice (neither in males nor in females) (Fig. 3C) , suggesting that the observed effects of phenothiazine compounds are pleiotropic.
Discussion
Curbing oxidative stress via phagocyte NADPH oxidase (aka gp91 phox or NOX2) inhibition has been proposed as a strategy for G93A /NOX2 deficient hemizygous (NOX2 Y/ À , blue) males were compared to SOD1 G93A /WT littermates (NOX2 Y/ þ , purple) and historical SOD1 G93A males in the hybrid B6SJL background (black), (B) Double transgenic SOD1 G93A /NOX2 deficient homozygous (NOX2 À / À , red) females were compared to SOD1 G93A /heterozygous littermates (NOX2 þ /-, green) and historical SOD1 G93A females in the hybrid B6SJL background (black). Average survival and number of animals per group are indicated, log-rank (Mantel-Cox) test. (C) mRNA levels of the NOX2 subunit p47phox and neuronal (NEFL), microglial (Iba1, CD68) and astrocyte (GFAP) markers were assessed using qPCR in the spinal cord of SOD1 G93A mice crossed with NOX2 KO mice (n ¼6 males and n ¼5 females) and compared to NOX2 WT littermates (n¼ 4 males and n ¼ 4 females) and non-carriers (n¼ 4 males and n ¼ 4 females). Expression values were normalized to geometric mean of two house-keeping genes (GAPDH and HPRT) and expressed as a fold-change of SOD1 G93A non-carrier mice (NC). Values are presented as mean 7 SEM. Mann-Whitney test, *po 0.05, **p o 0.01, ***p o0.001.
the treatment of ALS [8, 32] . This hypothesis has so far not been validated, as clinically relevant specific NOX2 inhibitors are not yet available. Apocynin, an antioxidant molecule with a complex mechanism of action [10, 33] commonly advertised as a NOX inhibitor, has been administered to SOD1 G93A mice; however, it failed to improve symptoms [34, 35] . In an effort to identify small molecule NOX inhibitors, we have recently characterized thioridazine and other N-substituted phenothiazines as pan-NOX inhibitors [12] . Although phenothiazines have numerous modes of action in the CNS, they represent an interesting tool for target validation because their concentration in the CNS upon i.p. injection is compatible with NOX inhibition. In addition, perphenazine and thioridazine are already approved for human use allowing potential straightforward repositioning of these compounds into a clinical trial for ALS.
In a first set of experiments, we verified the induction of NOX2 expression in the CNS of ALS mice in three etiologically different disease models. This finding is compatible with involvement of NOX2 in a common pathomechanism for ALS and possibly other neurodegenerative disorders [7] . More detailed investigation in SOD1 G93A mice showed NOX2 up-regulation at both transcriptional and protein levels and identified a related up-regulation of the subunits necessary for NOX2 activity. The levels of NOX2 are also increased in human ALS samples. We observed a typical microglial staining for NOX2 in human spinal cord, corroborating previous reports [7, 8] and recent RNAseq data showing that NOX2 expression is restricted to microglia in the healthy mouse and human CNS ( [36, 37] , see also http://web.stanford.edu/group/ barres_lab/brain_rnaseq.html). NOX2 increase in the spinal cord of ALS mice and patients is most likely due to proliferation and activation of microglia although infiltration of mononuclear inflammatory cells may account at least in part for this increase. It is indeed difficult to distinguish the respective impact of macrophages and parenchymal microglia as they share the same specific markers for both resting and active states, including NOX2. It is unlikely that the infiltration of T-lymphocytes accounts for this increase since the expression of NOX2 in T-cells is very low (if any) [38] . In contrast, based on the RNAseq data cited above, the presence of NOX4 in spinal cord homogenates might be due to its endothelial expression. The low level expression of NOX1 is likely due to vascular smooth muscle cells; however, the marked NOX3 Fig. 5 . In vivo pharmacology of perphenazine and thioridazine. Brain concentrations of compounds were determined upon i.p. injection of (A) perphenazine, 3 mg/kg and (B) thioridazine, 10 mg/kg. Dotted line shows IC 50 value for NOX2 inhibition in Amplex red assay in PLB985 cells [12] . (C-F) LC/MS/MS quantification of HE oxidation products measured in the spinal cord tissue of SOD1 G93A mice (females, 110 days) following administration of thioridazine or saline and non-carriers (NC). HE was administered intraspinally 30 min before collection of spinal cord. The following HE oxidation products were detected and quantified (C) 2-hydroxyethidium (2-OH-E þ ), the specific product of the reaction of HE with O 2 •- [30] ; (D) ethidium (E þ ) and (E) ethidium dimers (E þ dimer) which are formed by unspecified oxidants [31] and (F) 2-chlorethidium (2-Cl-E þ ), a specific product formed from the reaction of HE with hypochlorous acid (HOCl) [21] . The values are presented as ratio to total HE detected (individual values and mean). Mann-Whitney test, *p o 0.05, **p o 0.01. Thio -thioridazine. upregulation in the SOD1 G93A model is puzzling and was not anticipated since NOX3 expression is almost completely restricted to the inner ear and to embryonic tissue. Unfortunately, the lack of validated mouse NOX3 antibodies is a limitation to identify the specific cellular localization of NOX3 in the spinal cord of ALS mice. Another interesting observation is that DUOXA1 is expressed in the spinal cord tissue and upregulated with the course of the disease. DUOXA1 is known as a subunit necessary for the activity of DUOX1. However DUOX1 was below detection levels in the analyzed tissues. This suggests a possible role for DUOXA1 in the CNS which is independent of DUOX1. Importantly, the increase in the expression of NOX enzymes was accompanied by an increase of ROS in the spinal cord in vivo. We used LC/MS/MS analysis of HE and its oxidation products as, unlike the standard fluorescence detection of HE oxidation, it allows for the detection and quantification of specific products of HE oxidation, including those with O 2
• À and hypochlorous acid, the latter usually produced by MPO in activated neutrophils. This method indicated that general oxidation is increased in the spinal cord of SOD1 G93A mice, but also that the increased levels of O 2 • À , the specific primary product of NOX, were decreased in thioridazine-treated animals, compatible with the notion that NOX is inhibited in vivo. Conversely, the levels of chlorinated HE, the product of MPO activity, were unchanged. The absence of MPO activity likely reflects the absence of neutrophil infiltration in the spinal cord of ALS mice. Interestingly, the increase in ROS measured in spinal cord (1.5-fold) appears substantially lower than the induction of NOX2 mRNA ( 420-fold) in ALS spinal cord. This may suggest that although NOX2 is present, it may not be fully activated. The expression of regulatory subunits (p47 phox , p67 phox and p40 phox ) shows 2-5 fold increase. This might limit NOX2-derived superoxide generation since the active complex requires equimolar assembly of all subunits. In addition NOX2 requires activation for the generation of ROS. This is illustrated by ROS measurements in microglial cells: increased NOX2 expression upon LPS pretreatment is not sufficient to generate ROS and requires additional stimulation with PMA, a PKC activator. In addition to NOX, other sources of ROS, including mitochondria, xanthine oxidase, cytochrome P450 or iNOS, may be relevant sources of oxidative stress in ALS and other neuroinflammatory conditions [39] [40] [41] . It is possible that thioridazine interferes with one or several of these systems [42, 43] .
Despite strong up-regulation of the NOX2 complex in SOD1 G93A mice, associated with increased O 2 • À in vivo, which can be mitigated by thioridazine treatment, we found no improvement in survival following pharmacological intervention with thioridazine or perphenazine. A possible explanation for the lack of impact on survival of the N-substituted phenothiazine treatment is their insufficient CNS exposure. Although the concentrations of perphenazine and thioridazine in the CNS were above or higher than the IC 50 for NOX2 inhibition for at least 8 h, we cannot exclude that CNS exposure obtained upon a single injection of the drug was not sufficient in a 24 h period. We selected a single daily dose in order to avoid long period of drowsiness in mice induced by high doses of phenothiazines. Another possible explanation is that NOX inhibition alone is insufficient to slow down disease progression and to improve survival as the breeding of SOD1 G93A mice with NOX1
and NOX2-deficient mice did not impact the survival or motor neuron loss. Our results are in disagreement with previous studies, which reported increased survival of 13 days [8] and 97 days [32] of ALS mice cross-bred with NOX2-deficient mice and 33 days for NOX1 genetic ablation [32] . The discrepancy with the first report (13 days) is most likely due to genetic background effect. SOD1 G93A mice used in this study are in the hybrid B6/SJL background while NOX2-deficient mice are in the B6 background. The survival of mice with SOD1 G93A mutation is increased when the transgene is carried in a pure B6 background [25] . We similarly observed an increased survival of 12 days in males in the mixed background compared to the hybrid background for both breeding with NOX2 and NOX1-deficient mice. The massive survival effect of NOX2 (and to a less extent NOX1) deletion reported by others [32] could not be reproduced. In our study, we followed specific standard operating procedures for pharmacological treatments [44] and used non-carrier littermates as control for evaluation of survival. Inducible genetic ablation of NOX2 specifically in microglia would provide a further insight into its contribution to the progression of ALS. Although chronic administration of perphenazine or thioridazine failed to improve the survival of ALS mice, both molecules modified specific molecular markers and clinical symptoms in this model. Undeniably, in addition to NOX inhibitory activity, perphenazine and thioridazine have multiple actions in the CNS, such as D2 dopamine receptor antagonism, among others (reviewed in [45, 46] ). Strikingly, despite high structural similarities, the two N-substituted phenothiazines tested in this study had opposite effects on glial markers. Perphenazine treatment showed an increase of the expression of NOX2 and CD68 and a trend to an increase of GFAP and Iba1, while thioridazine treatment had the opposite effect. The reason for this difference is unclear, however we cannot exclude that the less favorable pharmacokinetics profile of perphenazine is involved. Besides, different aspects of disease progression were affected by the two treatments. Perphenazine slowed down the weight loss of SOD1 G93A mice, which could be explained by the known weigh gain promoting effect of antipsychotics [47] . Thioridazine treatment resulted in an immediate enhancement of rotarod performance to the level of controls during early disease stages (day 70-day 100). This is a potentially interesting finding; however it is not clear whether this effect is due to NOX inhibition.
Conclusion
In this study, we demonstrate that the expression of NOX2 isoform of the NADPH oxidase family is strongly increased in the spinal cord of ALS models. NOX2 expression is microglia specific and correlates with the level of microgliosis and severity of disease. As opposed to former studies, constitutive genetic deletion of NOX1 or NOX2 did not improve survival of ALS mice. Using a novel LC/MS/MS based method we were able to detect specific increase of intraspinal superoxide in ALS mice, which could be mitigated by thioridazine, a broad spectrum NOX inhibitor. Thioridazine showed favorable CNS pharmacokinetics and moderate enhancement of motor function without an impact on the later disease stages and mortality. While thioridazine is an imperfect tool to study the involvement of NOX in ALS, novel effort for identification of NOX2 inhibitors [11] and the recently discovered BBB permeable specific NOX2 inhibitor GSK2795039 [10] may represent favorable approaches for further validation of the therapeutic potential of NOX inhibition for the treatment of ALS and other neurodegenerative diseases.
